Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today reported it has filed for a utility patent for its multi-parameter, noninvasive sepsis monitor. This submission follows a provisional patent application on sepsis monitoring the Company filed in January 2021.
“Sepsis is one of the biggest problems in hospitals today. Globally, over 48 million cases of sepsis are reported every year, with 11 million deaths. In the U.S. alone, over 1.7 million adults will develop sepsis annually, resulting in approximately 300,000 deaths,” said Thomas Sandgaard, CEO of Zynex. “Conventional patient monitors give insufficient warning of deteriorating patient health or the onset of potentially serious physiological conditions resulting from sepsis. Our monitor is designed to measure a patient’s condition noninvasively and provide caregivers with an advanced warning or prediction of the onset of sepsis, and can be configured to provide or facilitate automatic intervention or treatment of sepsis and conditions resulting from sepsis.”
Sepsis is a life-threatening medical condition characterized by the body-wide inflammatory response or reaction that presents in response to infection. The inflammatory response triggered by the immune response can cause body-wide tissue damage, even to areas not local to the initial infection. Bacterial infections are the most common cause of sepsis, but sepsis can also be caused by fungal, parasitic, or viral infections. As an ineffectively treated infection progresses, toxins from the infection may circulate in the bloodstream, causing damage to other organs (such as the brain, heart, lungs, kidneys, liver, etc.) and tissues. As the damage progresses, septic shock and a fatal decline in blood pressure may occur; patients with additional medical conditions and risk factors have an increased likelihood of death.
Sepsis treatment spans multiple days to weeks, often in an intensive care environment and is detected through blood cultures, blood-gas analysis, kidney and other organ functional tests, platelet and white blood cell counts, additional imaging, urine testing, cerebrospinal fluid tests, etc.
The signs and symptoms of sepsis often may be subtle. The low survival rate of patients with severe sepsis indicates that current sepsis identification strategies, tools, and methods may be lacking.
For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybersecurity, go to AI-Techpark.com.